A radiopharmaceuticals startup raises $175 million

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. 

Hello! Today, we talk about how much dang money some CEOs still make, despite the slowdown in the biotech industry. We also see Dupixent approved for a huge new indication, and more.

Prime Medicine narrows targets, gets cash influx

The high-profile CRISPR editing company Prime Medicine is in a financial crunch, and is scaling back on once-ambitious plans. The company originally targeted 18 diseases, but now will focus on just three: chronic granulomatous disease, Wilson’s disease, and cystic fibrosis.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In